MeSH D000071057 - tardive dyskinesia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D004409:Drug-induced dyskinesia
D000071057:
Tardive dyskinesia
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Neurocrine Biosciences | Valbenazine | Ingrezza | 2027-11-08 | 2017-04-11 | ||
| Teva | Deutetrabenazine | Austedo | 2031-04-03 | 2017-04-03 | $1,225 M | Y2023 |
Clinical Trials
Historical Success Rate
Phase 1
80%4/5
Phase 2
33%4/12
Phase 3
25%2/8
Approved: 1Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use